Telomerase reverse transcriptase ( XXXX ) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of @entity1179 with immortalizing genetic change.

@entity1 @entity10207 @entity1494 @entity1179 @entity189 @entity59802 @entity150 @entity2215 @entity2335
AIMS: To better understand the genetic ontogeny of @entity1179 of @entity1494 , we analyzed telomerase reverse transcriptase ( @entity2215 ) promoter mutation status in a group of 26 @entity1179 in comparison with the mutation status of @entity189 with inverted growth (26 cases), conventional @entity189 (36 Ta noninvasive @entity189 , 35 T2 invasive @entity189 ), and @entity2335 (25 cases). METHODS AND RESULTS: @entity2215 promoter mutations in @entity1179 , @entity189 with inverted growth, @entity189 , and @entity2335 were 15% (4/26), 58% (15/26), 63% (45/71), and 0% (0/25), respectively. @entity10207 mutations were the predominant mutations (97%) found in @entity150 while @entity59802 aberrations occurred in only about 3% of @entity150 . In the @entity1179 group, @entity2215 mutation occurred predominantly in female @entity1 (P=0.006). Among @entity189 , @entity2215 promoter mutation status did not correlate with gender, histologic grade or pathologic stage. CONCLUSIONS: @entity2215 promoter mutations were found in 15% of @entity1179 . Our data suggest that there is a subpopulation of @entity1179 that shares a carcinogenetic pathway with @entity189 with inverted growth and conventional @entity189 . Caution is warranted in exploring @entity2215 promoter mutation status as a screening or adjunct diagnostic test for @entity150 . This article is protected by copyright. All rights reserved.
